We believe that hypercalcaemia after tamoxifen may signify tumour response and be a reason for continuing with tamoxifen and treating the hypercalcaemia. This is supported by a report of tamoxifen "flare" in metastatic breast cancer and the observation that acute exacerbation of bone pain in patients with breast cancer after tamoxifen may be associated with tumour response.'5 The mechanism of tamoxifeninduced tumour response needs further investigation, since acute hypercalcaemia is not seen in patients responding to chemotherapy or oophorectomy.
Hydrallazine-induced SLE-like syndrome presenting as a leg ulcer
The use of hydrallazine for systemic hypertension may be complicated by a syndrome resembling systemic lupus erythematosus (SLE) in 10-15",, of patients after cumulative doses exceeding 100 g.' We describe a patient who presented with a painful leg ulcer.
Case report
A 50-year-old man admitted in January 1979 had a nine-week history of a painful ulcer above the right heel, which had steadily enlarged and prevented walking. He had a nine-month history of symptoms suggestive of Raynaud's phenomenon, joint pains for three months, malaise for six weeks, and an itchy rash over the left shin and forearm for one week. Malignant hypertension was diagnosed in 1970 (blood pressure 250/130 mm Hg) and treatment instituted with debrisoquine. In 1976 he was admitted with a blood pressure of 270/180 mm Hg and hydrallazine treatment was begun (150 mg daily). There was no diabetes mellitus, vascular insufficiency, or trauma. He smoked 15 cigarettes daily.
He was drowsy, with mild tachycardia (100/min) and low-grade fever (37 5 C). Blood pressure was 220/150 mm Hg (supine) and 190/135 mm Hg (erect). The ulcer (3-5 cm diameter), directly over the right tendo Achillis, wvas superficial, but the edge was discoloured and the base encrusted with old blood. There was no arterial or venous insufficiency or regional lymphadenopathy. There was severe wasting of the right quadriceps muscle, equinus deformity of the right ankle, and a diffuse purpuric rash over the left shin and forearm.
Haemoglobin concentration was 12 8 g/'dl but white cell and platelet counts were normal. Plasma viscosity was raised (1-92 mPa s; 1-92 cp), serum iron concentration 6 9 [emol l (38 5 fLg,100 ml), total iron-binding capacity 47 ,umol/l (262 5 zg, 100 ml), blood urea concentration 8 1 mmolj'l (48 6 mg/100 ml), and creatinine clearance 52 mljmin. Titre for antinuclear factor (ANF) was 1/320 and DNA antibody binding 21 110. IgM concentration was 9 0 g 1, but complement values were normal. Random blood glucose estimations, chest and ankle radiographs, and Wassermann and latex fixation tests showed no abnormalities. The patient was a slow acetylator as assessed by sulphadimidine clearance. A biopsy specimen of the ulcer disclosed fibrosing granulation tissue. All these features suggested that an SLE-like syndrome may have caused this patient's indolent ulcer. Since total hydrallazine exposure may have been relevant the drug was replaced by atenolol and bendrofluazide. With bed rest, raising the leg, and cleaning the ulcer locally his condition rapidly improved. The rash disappeared five days after stopping hydrallazine, and by one week the ulcer was healing; this was accelerated by applying split-skin grafts. At discharge plasma v-iscosity was 1-7 mPa s (1 7 cp). After four months he was in good health and had returned to work. The ulcer had healed, and after physiotherapy his ankle and thigh had returned to normal. Blood pressure was controlled at 140/90 mm Hg. Plasma viscosity, ANF titres, and DNA antibody binding were unchanged.
Comment
Dubois2 reviewed 520 cases of idiopathic SLE and found a 5% incidence of leg ulceration but this complication has not been reported in hydrallazine-induced SLE. About 1000 of cases of SLE may be caused by drugs, notably hydrallazine. Patients may develop a positive ANF titre with hydrallazine without having SLE-like symptoms.' This phenomenon was also shown for prazosin.4 Druginduced SLE differs from idiopathic SLE in affecting older people, relatively more men, and the lung and kidney less often; DNA antibody binding is under 301 .3 Some 960) of patients with druginduced SLE are slow acetylators.:' 5 Although first described in patients taking large daily doses of hydrallazine (400 mg),3 the syndrome may occur with lower doses (150 mg)5; the cumulative dosage appears to be more important. Symptoms usually disappear within four months of stopping hydrallazine, but ANF titres and DNA antibody binding may take up to six years to return to normal.5
The relation between toxic symptoms and hypertensive control is not clear. Perry3 suggested that toxicity was associated with control of blood pressure and that suddenly stopping treatment led to rebound hypertension. In our case toxicity was associated with failure of hypertensive control. We suggest that acetylator states of all patients taking long-term hydrallazine should be determined to identify those at risk from drug-induced SLE. Once hypertension is controlled the daily dose should be reduced to the minimum needed to maintain normal blood pressure. 
Methods and results
Wc reviewed retrospectively 67 consecutive scans performed on 61 patients with PUO referred to our department in one year. The PUO had been prcsent for several days to several weeks, and routine investigations including blood, sputum, and urine cultures, chest radiography, and intravenous urography, had not determined its origin. Imaging was performed 48 and 72 hours aftcr intravenous injection of 75-100 MBq (2-2-7 mCi) gallium citrate ('7Ga; Radiochemical Centre). Patients were not preparcd before injection, but unless contraindicated Dorbanex tablets (danthronpoloxamer) wvere given 12-hourly for 72 hours afterwards. Imaging was performed with an Ohio Nuclear 84 double-hcaded rectilinear scanner with 5 :1 ratio minification using a high-energy collimator and an analyser setting that accepted the 185 and 296 keV peaks of 6 7Ga. Patients were imaged from neck to thigh. When indicated, a liver-spleen scan with ssm'Fc-sulphur colloid was performed after the 67Ga scan at 72 hours, the patient being kept in the same position to permit superimposition of the scans. Gallium-67 scans wvere regarded as normal when uptake was seen only in sitcs of physiological accumulation, and abnormal when uptake was seen at other sites, provided relative uptake increased between 48 and 72 hours.
Of the 67 67 Ga scans, 50 were abnormal. Most sites of abnormal uptake were in the abdomen (table), miscellaneous sites consisting mainly of
